Next Article in Journal
Juvenile Moyamoya and Craniosynostosis in a Child with Deletion 1p32p31: Expanding the Clinical Spectrum of 1p32p31 Deletion Syndrome and a Review of the Literature
Next Article in Special Issue
The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
Previous Article in Journal
Effects of Metal Ions, Temperature, and a Denaturant on the Oxidative Folding Pathways of Bovine α-Lactalbumin
Previous Article in Special Issue
Can We Predict the Efficacy of Anti-TNF-α Agents?
Review

Anti-NKG2D mAb: A New Treatment for Crohn’s Disease?

1
Gastro unit, Medical Division, Hvidovre University Hospital, Kettegård Alle 30, DK-2650 Hvidovre, Denmark
2
Medical Affairs, Janssen Immunology, Janssen-Cilag A/S, Bregnerødvej 133, DK-3460 Birkerød, Denmark
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(9), 1997; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091997
Received: 13 July 2017 / Revised: 24 August 2017 / Accepted: 11 September 2017 / Published: 16 September 2017
Crohn’s disease (CD) and ulcerative colitis (UC) are immunologically-mediated, debilitating conditions resulting from destructive inflammation of the gastrointestinal tract. The pathogenesis of IBD is incompletely understood, but is considered to be the result of an abnormal immune response with a wide range of cell types and proteins involved. Natural Killer Group 2D (NKG2D) is an activating receptor constitutively expressed on human Natural Killer (NK), γδ T, mucosal-associated invariant T (MAIT), CD56+ T, and CD8+ T cells. Activation of NKG2D triggers cellular proliferation, cytokine production, and target cell killing. Research into the NKG2D mechanism of action has primarily been focused on cancer and viral infections where cytotoxicity evasion is a concern. In human inflammatory bowel disease (IBD) this system is less characterized, but the ligands have been shown to be highly expressed during intestinal inflammation and the following receptor activation may contribute to tissue degeneration. A recent phase II clinical trial showed that an antibody against NKG2D induced clinical remission of CD in some patients, suggesting NKG2D and its ligands to be of importance in the pathogenesis of CD. This review will describe the receptor and its ligands in intestinal tissues and the clinical potential of blocking NKG2D in Crohn’s disease. View Full-Text
Keywords: Crohn’s Disease; IBD; NKG2D; MICA; MICB; ULBP Crohn’s Disease; IBD; NKG2D; MICA; MICB; ULBP
Show Figures

Graphical abstract

MDPI and ACS Style

Vadstrup, K.; Bendtsen, F. Anti-NKG2D mAb: A New Treatment for Crohn’s Disease? Int. J. Mol. Sci. 2017, 18, 1997. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091997

AMA Style

Vadstrup K, Bendtsen F. Anti-NKG2D mAb: A New Treatment for Crohn’s Disease? International Journal of Molecular Sciences. 2017; 18(9):1997. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091997

Chicago/Turabian Style

Vadstrup, Kasper, and Flemming Bendtsen. 2017. "Anti-NKG2D mAb: A New Treatment for Crohn’s Disease?" International Journal of Molecular Sciences 18, no. 9: 1997. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18091997

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop